Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

Last updated: November 4, 2025
Sponsor: Pacira Pharmaceuticals, Inc
Overall Status: Active - Recruiting

Phase

1

Condition

Chronic Pain

Acute Pain

Pain

Treatment

bupivacaine

EXPAREL

Clinical Study ID

NCT06271265
402-C-125
  • Ages < 6
  • All Genders

Study Summary

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

Eligibility Criteria

Inclusion

Inclusion Criteria:

All of the following inclusion criteria must be met for eligibility:

  1. Pediatric participants with congenital heart defects planned to undergo cardiacsurgery with cardiopulmonary bypass

  2. Male or female participants from 0 to less than 6 years of age on the day ofsurgery: 2 years to less than 6 years of age for Part 1; 6 months to less than 2years of age for Part 2; 0 to less than 6 months of age for Part 3

  3. American Society of Anesthesiologists (ASA) Classes 1 through 4.

  4. Parent/guardian is able to speak, read, and understand the language of the ICF andprovide informed consent for the participant.

  5. Parent/guardian is able to adhere to the study visit schedule and complete all studyassessments for the participant.

Exclusion

Exclusion Criteria:

Exclusion Criteria:

A participant will not be eligible for the study if any of the following exclusion criteria are met:

  1. History of hypersensitivity or idiosyncratic reactions or contradictions to EXPAREL,bupivacaine HCl, or other amide-type local anesthetics or to opioid medications

  2. Administration of EXPAREL or bupivacaine HCl within 30 days prior to IPadministration

  3. Administration of an IP within 30 days or 5 elimination half-lives of such IP,whichever is longer, prior to IP administration, or planned administration ofanother IP or procedure during participation in this study

  4. History of preterm birth (before 35 weeks of pregnancy)

  5. History of coagulopathies or immunodeficiency disorders

  6. Disease or condition that, in the opinion of the Investigator, indicates anincreased vulnerability to IPs and/or procedures

  7. Recent or potential exposure to COVID-19

  8. Cardiac surgery has been canceled and cannot be rescheduled within 30 days ofsigning the ICF because of any reason.

  9. Necessity in delayed wound closure

  10. Informed consent withdrawn before randomization

Study Design

Total Participants: 48
Treatment Group(s): 2
Primary Treatment: bupivacaine
Phase: 1
Study Start date:
March 29, 2024
Estimated Completion Date:
January 31, 2027

Study Description

This study will be conducted in 3 Parts (Part 1, Part 2, and Part 3) and a total of approximately 48 male and female subjects will be enrolled.

Part 1 will enroll approximately 16 subjects, aged 2 to less than 6 years to obtain information on PK and safety. Subjects will be randomized 1:1 (8 EXPAREL subjects and 8 bupivacaine HCl subjects) to receive either a single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) or 0.25% bupivacaine HCl 2 mg/kg (not to exceed a maximum total dose of 175 mg) using LIA. The overall PK and safety profiles from Part 1 will be completed, analyzed, and reviewed to establish an appropriate study drug dose for Part 2.

Subject enrollment for Part 2 will commence upon complete enrollment of Part 1, establishment of an appropriate study drug dose from the PK, and safety analysis of Part 1 and Data Safety Monitoring Board (DSMB) recommendations to proceed to Part 2. Part 2 will enroll approximately 16 subjects, aged 6 months to less than 2 years to obtain information on PK and safety. Subjects will be randomized 1:1 (8 EXPAREL subjects and 8 bupivacaine HCl subjects) to receive either a single dose of EXPAREL or 0.25% bupivacaine HCl using LIA. The overall PK and safety profiles from Part 2 will be completed, analyzed, and reviewed to establish an appropriate study drug dose for Part 3.

Subject enrollment for Part 3 will commence upon complete enrollment of Part 2, establishment of an appropriate study drug dose from the PK and safety analysis of Part 2, and DSMB recommendations to proceed to Part 3.

Part 3 will enroll approximately 16 subjects aged 0 to less than 6 months to obtain information on PK and safety. Subjects will be randomized 1:1 (8 EXPAREL subjects and 8 bupivacaine HCL subjects) to receive either a single dose of EXPAREL or 0.25% bupivacaine HCl using LIA.

Connect with a study center

  • St. Louis Children's Hospital (SLCH)

    St Louis 4407066, Missouri 4398678 63110
    United States

    Active - Recruiting

  • Duke University Health System

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Duke University Health System

    Durham 4464368, North Carolina 4482348 27710
    United States

    Active - Recruiting

  • University of Oklahoma (OU) - Medical Center - The Children's Hospital

    Oklahoma City, Oklahoma 73104
    United States

    Site Not Available

  • University of Oklahoma (OU) - Medical Center - The Children's Hospital

    Oklahoma City 4544349, Oklahoma 4544379 73104
    United States

    Active - Recruiting

  • The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School

    Houston, Texas 77030
    United States

    Site Not Available

  • The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School

    Houston 4699066, Texas 4736286 77030
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.